Brief: Novartis Completes Acquisition Of Avidity Biosciences
27/02/2026 14:03
Feb 27 (Reuters) - NOVARTIS NOVN.S: NOVARTIS SUCCESSFULLY COMPLETES ACQUISITION OF AVIDITY BIOSCIENCES, STRENGTHENING LATE-STAGE NEUROSCIENCE PIPELINE AND ADVANCING XRNA STRATEGY NOVARTIS - UNLOCKS MULTI-BILLION-DOLLAR OPPORTUNITIES WITH LAUNCHES BEFORE 2030 NOVARTIS - STRENGTHENS LATE-STAGE PIPELINE TO FURTHER SUPPORT 2025-2030 NET SALES CAGR OF 5-6% CC AND MID TO LONG TERM GROWTH OUTLOOK NOVARTIS - HOLDERS OF AVIDITY COMMON STOCK BECAME ENTITLED TO RECEIVE USD 72.00 PER SHARE IN CASH Source text: ID:nGNE1VQHNW Further company coverage: NOVN.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'